Table 3.

Treatment-emergent adverse events related to patiromer (safety population; n=632)

No. of Patients (%)	Severity	Patients with Stage 3b–5 CKD (n=421)	Patients with Stage 1–3a CKD (n=211)
≥1 adverse event	Any severity	67 (15.9)	25 (11.8)
	Mild	45 (10.7)	18 (8.5)
	Moderate	22 (5.2)	7 (3.3)
	Severe	0 (0.0)	0 (0.0)
Gastrointestinal disorders	Any severity	54 (12.8)	13 (6.2)
	Mild	36 (8.6)	10 (4.7)
	Moderate	18 (4.3)	3 (1.4)
	Severe	0 (0.0)	0 (0.0)
Constipation	Any severity	30 (7.1)	6 (2.8)
	Mild	21 (5.0)	6 (2.8)
	Moderate	9 (2.1)	0 (0.0)
	Severe	0 (0.0)	0 (0.0)
Diarrhea	Any severity	12 (2.9)	4 (1.9)
	Mild	8 (1.9)	4 (1.9)
	Moderate	4 (1.0)	0 (0.0)
	Severe	0 (0.0)	0 (0.0)
Metabolism and nutrition disorders	Any severity	16 (3.8)	7 (3.3)
	Mild	13 (3.1)	4 (1.9)
	Moderate	3 (0.7)	3 (1.4)
	Severe	0 (0.0)	0 (0.0)
Hypomagnesemia	Any severity	9 (2.1)	5 (2.4)
	Mild	8 (1.9)	3 (1.4)
	Moderate	1 (0.2)	2 (0.9)
	Severe	0 (0.0)	0 (0.0)

This table summarizes adverse events during the first 4 weeks after the start of patiromer treatment (defined as onset on or before study day 32), regardless of the date of treatment discontinuation. Adverse event that occurred in ≥2% of patients in either subgroup.